| Autor: |
Peters ZJ; Psychological Health Center of Excellence, Defense Health Agency, Silver Spring, Maryland, USA.; Salient CRGT, Inc., Fairfax, Virginia, USA., Kincaid MW; Psychological Health Center of Excellence, Defense Health Agency, Silver Spring, Maryland, USA.; Salient CRGT, Inc., Fairfax, Virginia, USA., Greenberg JG; Psychological Health Center of Excellence, Defense Health Agency, Silver Spring, Maryland, USA.; Salient CRGT, Inc., Fairfax, Virginia, USA., Quah RF; Psychological Health Center of Excellence, Defense Health Agency, Silver Spring, Maryland, USA.; Salient CRGT, Inc., Fairfax, Virginia, USA., Curry JC; Psychological Health Center of Excellence, Defense Health Agency, Silver Spring, Maryland, USA. |
| Abstrakt: |
Background: Alcohol-use disorders (AUD) pose a significant challenge for the United States (US) military. The US Department of Defense has strongly recommended several medications for use in the treatment of patients with diagnosed AUD. This study assessed the prescription of medications for active duty service members (ADSMs) diagnosed with AUD in the US Military Health System (MHS). Methods: Rates of prescription orders were retrospectively examined from 2010 to 2017 among ADSMs with an incident diagnosis of moderate-to-severe AUD. The rate of prescription orders was defined as the proportion of ADSMs with an ICD-9 or ICD-10 diagnosis code of alcohol dependence who received an order for acamprosate, disulfiram, naltrexone, and/or topiramate at a military treatment facility in the year following their incident diagnosis. Results: ADSMs receiving an order for at least one medication in the year following their incident AUD diagnosis increased from 8.8% in 2010 to 16.2% in 2017 (RR = 1.84, 95% CI, 1.76, 1.93). Oral naltrexone was ordered most frequently among this patient population, while injectable naltrexone, a medication option meant to ease and improve adherence, was ordered for a smaller proportion of patients. Conclusions: Most ADSMs who might benefit from prescriptions for AUD are not receiving them as part of their treatment despite strong clinical evidence and Department of Defense policy support for their use among this cohort. |
